Table 5.
Comparison of frequency of dose reduction of Peg-IFN, early termination, and SAEs in patients with CHB versus CHC
| 24-week group, n/N | P | 48-week group, n/N | P | |||
|---|---|---|---|---|---|---|
| CHB | CHC | CHB | CHC | |||
| Dose reduction and early termination | 3/31 (9.7%) | 7/57 (12.3%) | 1.000 | 5/25 (20.0%) | 6/46 (13.0%) | 0.501 |
| Early termination | 0/31 (0.0%) | 2/57 (3.5%) | 0.538 | 1/25 (4.0%) | 4/46 (8.7%) | 0.650 |
| SAEs | 0/31 (0.0%) | 3/57 (5.3%) | 0.549 | 1/25 (4.0%) | 4/46 (8.7%) | 0.650 |
SAEs severe adverse events